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BACKGROUND: Acute outpatient management of venous thromboembolism (VTE), which includes pulmonary embolism (PE) 
and deep vein thrombosis (DVT), is perceived to be as safe as inpatient management in some settings. How widely this strat-
egy is used is not well documented.
METHODS AND RESULTS: Using MarketScan administrative claims databases for years 2011 through 2018, we identified patients 
with International Classification of Diseases (ICD) codes indicating incident VTE and trends in the use of acute outpatient 
management. We also evaluated healthcare utilization and hospitalized bleeding events in the 6 months following the incident 
VTE event. A total of 200 346 patients with VTE were included, of whom 50% had evidence of PE. Acute outpatient manage-
ment was used for 18% of those with PE and 57% of those with DVT only, and for both DVT and PE its use increased from 
2011 to 2018. Outpatient management was less prevalent among patients with cancer, higher Charlson comorbidity index 
scores, and whose primary treatment was warfarin as compared with a direct oral anticoagulant. Healthcare utilization in the 
6 months following the incident VTE event was generally lower among patients managed acutely as outpatients, regardless of 
initial presentation. Acute outpatient management was associated with lower hazard ratios of incident bleeding risk for both 
patients who initially presented with PE (0.71 [95% CI, 0.61, 0.82]) and DVT only (0.59 [95% CI, 0.54, 0.64]).
CONCLUSIONS: Outpatient management of VTE is increasing. In the present analysis, it was associated with lower subsequent 
healthcare utilization and fewer bleeding events. However, this may be because healthier patients were managed on an out-
patient basis.
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Venous thromboembolism (VTE), which consists of both deep vein thrombosis (DVT) and pulmonary embolism (PE), affects ≈1.1 million Americans an-
nually.1 The landscape of VTE diagnosis and manage-
ment has changed dramatically in the past 2 decades. 
In regard to acute out- of- hospital management, the 
2016 American College of Chest Physicians Guideline 
and Expert Panel Report states that “In patients with 
low- risk PE and whose home circumstances are 
adequate, we suggest at home or early discharge over 
standard discharge (eg, after the first 5 days of treat-
ment).”2 This is a Grade 2B recommendation, signifying 
that it is a “weak” (Grade 2) recommendation based 
on “moderate” (Grade B) quality evidence. Given that 
patients with DVT events but no documented PE are 
at lower risk of adverse outcomes, outpatient manage-
ment in this context has been widespread for some 
time.2,3
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Outpatient VTE treatment has the potential to re-
duce medical costs,4 be less burdensome to patients, 
and in low- risk situations, yield similar outcomes.2 
However, there are important barriers to outpatient 
management; most prominently, fear of experiencing 
early complications and whether a local healthcare 
system can provide adequate initial care in the out-
patient setting.3 Little is known about how widely out-
patient management is presently being utilized or its 
real- world effectiveness.3,5
Outpatient treatment rates may have increased in 
recent years because of both (1) primary treatment 
with direct oral anticoagulants (DOACs) offering an 
all- oral VTE treatment option, and (2) improved iden-
tification of patients with low- risk PE. The availability 
of several DOACs (ie, dabigatran, rivaroxaban, apix-
aban, and edoxaban),6– 10 in addition to warfarin and 
low- molecular- weight heparin, have expanded the po-
tential for outpatient VTE management.11 The DOACs 
have a more stable anticoagulant effect and require 
less monitoring. Additionally, some (ie, rivaroxaban and 
apixaban) do not require initial parenteral anticoagulant 
therapy.
The current prevalence of outpatient VTE man-
agement is unknown, since studies that have eval-
uated this question ended follow- up before the era 
of widespread DOAC use (ie, in the mid- 2010s or 
before).11– 17 Additionally, uncertainty remains about 
the association of outpatient versus inpatient man-
agement with subsequent healthcare utilization and 
bleeding risk in routine clinical settings. Herein we 
provide estimates of acute VTE management (out-
patient versus inpatient) in an insured population for 
the period from 2011 to 2018, overall and by several 
characteristics of the patient (ie, age, sex, comorbid-
ity burden, whether it was provoked by cancer), clin-
ical presentation (ie, PE or DVT- only), and initial oral 
anticoagulant (OAC) therapy (ie, DOAC versus warfa-
rin). Furthermore, we assess the association of acute 
outpatient versus inpatient management with subse-
quent healthcare utilization and bleeding events in 
the primary treatment period (ie, the first 6 months 
following the VTE event).
METHODS
IBM MarketScan Commercial Claims and Encounters 
and Medicare Supplemental and Coordination of 
Benefits databases for calendar years 2011 through 
2018 were used in the present analysis. These adminis-
trative databases contain individual- level, de- identified, 
Health Insurance Portability and Accountability Act of 
1996– compliant, healthcare claims information from 
US employers, health plans, hospitals, and Medicare 
programs.18 Individual- level identifiers are used to link 
data across enrollment records and inpatient, out-
patient, ancillary, and drug claims. Given the time-
frame under study, both International Classification of 
Diseases Ninth Revision and Tenth Revision (ICD- 9 and 
ICD- 10) codes were used. Since the MarketScan data-
bases are commercial insurance databases, individu-
als with no insurance are not included and individuals 
working at small companies are underrepresented. 
The University of Minnesota Institutional Review Board 
deemed this research exempt from review, and waived 
the need to obtain informed consent. Because of li-
censing restrictions, we cannot make available the 
data and study materials to other investigators to re-
produce results, but researchers may contact IBM 
Watson Health to obtain and license the data.
Identification of VTE Cases
We included in the present analysis individuals aged 18 
to 99 years with incident VTE, at least 1 prescription for 
an OAC within the 31 days before or after their first VTE 
claim, and ≥3 months of continuous enrollment before 
their first OAC prescription.19 As is common in analyses 
of administrative data, a “run- in” period (in this instance 
3 months) was utilized to allow for identification of inci-
dent events and to capture information on comorbidi-
ties before the incident event.20
CLINICAL PERSPECTIVE
What Is New?
• Acute outpatient management for venous 
thromboembolism was used for 18% of pa-
tients with pulmonary embolism and 57%  of 
patients with deep vein thrombosis only. Its use 
increased from 2011 to 2018.
• Patients managed acutely as outpatients 
had fewer comorbidities and in the following 
6  months had lower healthcare utilization and 
were less frequently hospitalized for bleeding 
events.
What Are the Clinical Implications?
• These data provide contemporary informa-
tion on the patterns of acute outpatient venous 
thromboembolism management.
• Our findings suggest that outpatient manage-
ment is not associated with substantial harm in 
appropriately selected patients.
Nonstandard Abbreviations and Acronyms




 http://ahajournals.org by on D
ecem
ber 3, 2021
J Am Heart Assoc. 2021;10:e020428. DOI: 10.1161/JAHA.120.020428 3
Lutsey et al Inpatient vs Outpatient Acute VTE Management
We defined VTE as having at least 1 inpatient claim 
for VTE or 2 outpatient claims for VTE, which were 
7 to 185  days apart, in any position, based on ICD 
codes (listed in Table S1). We identified OAC prescrip-
tions, using outpatient pharmaceutical claims data, 
by National Drug Codes indicating fills for apixaban, 
rivaroxaban, dabigatran, edoxaban, or warfarin. This 
VTE definition is similar to that used in a recent valida-
tion study by Sanfilippo et al, which reported a posi-
tive predictive value of 91%.21 The Sanfilippo definition 
was also based on 1 inpatient or 2 outpatient VTE 
claims, and required evidence of treatment. We fur-
ther classified VTE cases according to whether there 
were ICD codes for PE, or if the ICD codes only indi-
cated DVT (regardless of DVT site). This classification 
was chosen since there are less data supporting out-
patient PE treatment than outpatient DVT treatment, 
and so the likelihood of acute outpatient management 
is likely to differ by whether there was evidence of PE.
The initial sample included 553  387 patients with 
ICD codes indicating VTE aged 18 to 99 years. The an-
alytic sample was 432 950 once restricted to individu-
als ever prescribed an OAC between January 1, 2011 
and December 31, 2018; 273 938 after requiring the 
first OAC prescription be within 31 days of the VTE ICD 
code date; 203 289 after requiring ≥90 days of contin-
uous enrollment before the first OAC prescription; and 
finally, 200  346 after excluding individuals who used 
low- molecular- weight heparin as their sole anticoagu-
lant prescription.
Designation as Inpatient or Outpatient 
Acute Management
For each year MarketScan compiles all hospitalization 
claims into an inpatient encounters data set, and all 
outpatient encounters in an outpatient claims data set. 
Acute management was designated as inpatient or 
outpatient according to dates of VTE medical encoun-
ters in the data sets. We classified patients with VTE 
with both inpatient and outpatient claims according to 
which date came first: the date of the first qualifying 
inpatient claim or the date of the second qualifying out-
patient claim.
Postacute Management Healthcare 
Utilization and Hospitalized Bleeding
Healthcare utilization and hospitalized bleeding 
within 6  months (ie, 185  days) of the incident VTE 
event were evaluated. The timeframe was selected 
as the VTE primary treatment period is 3– 6 months,2 
and one would expect that most repercussions fol-
lowing a VTE would occur within the 6 months fol-
lowing the incident event.
Inpatient, outpatient, and emergency department 
utilization during the VTE primary treatment period 
were identified using the MarketScan inpatient and 
outpatient databases. The VTE primary treatment pe-
riod was defined as beginning on the date of the first 
OAC prescription fill and continuing until disenrollment 
or 185 days post the index date (whichever came first). 
Inpatient claims were used to determine number of 
hospitalizations and days hospitalized. Emergency de-
partment and outpatient office visits were enumerated 
from the outpatient claims and distinguished using in-
formation on place of service.
We also evaluated number of bleeding- related hos-
pitalizations and days hospitalized within 185 days of 
the incident event. Incident hospitalized bleeding was 
defined according to the Cunningham algorithm,22 as 
we have done previously.19,23
Assessment of Prespecified Covariates
Information before the OAC initiation date (minimum 
90- day run- in time) from all data sources in MarketScan 
(ie, demographic data, inpatient, outpatient, and phar-
macy claims) was used to derive prespecified covari-
ates. The Charlson comorbidity index was calculated 
using relevant ICD- 9 and ICD- 10 codes.24 It was cat-
egorized as 0 (none noted), 1– 2 (mild), 3– 4 (moderate), 
and ≥5 (severe).
Statistical Analysis
Analyses were stratified by PE (regardless of DVT sta-
tus) or DVT only. Logistic regression models were fit 
with outpatient versus inpatient management as the 
dependent variable and the following independent 
variables: calendar year, sex, age category (<65 years, 
≥65 years), prevalent cancer, Charlson comorbid-
ity index score category, and initial OAC prescribed 
(DOAC, warfarin). Results were used to estimate ad-
justed prevalences of outpatient management using 
marginal standardization.25,26 Adjustment was made 
for age, sex, and (when appropriate) calendar year, as 
specified in the Table and Figure footnotes.
In analyses of incident bleeding, Cox proportional 
hazards regression was used to calculate hazard ra-
tios and 95% CIs. Follow- up began at the date of the 
first OAC prescription filled. Person- time accrued until 
incident hospitalized bleeding, health plan disenroll-
ment, the end of study follow- up, or 185 days, which-
ever came first. In model 1, we adjusted for age, sex, 
and initial OAC prescribed (DOAC or warfarin). In model 
2, we further adjusted for Charlson comorbidity index 
categories.
When healthcare utilization was the outcome of 
interest, all outcomes were count data and, as such, 
negative binomial regression was used (ie, SAS 
GENMOD procedure with a negative binomial distribu-
tion and a log link). An offset of log follow- up time was 
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individuals. Incidence rate ratios and 95% CIs were es-
timated. Covariates were the same as for the incident 
bleeding analyses.
Sensitivity analyses were conducted requiring 
6 months of enrollment in the MarketScan database 
before incident VTE. Stata SE version 15 and SAS ver-
sion 9.4 were used for the analyses.
RESULTS
Overall, 37.6% of patients with acute VTE in our sample 
were initially treated as outpatients. When stratified by 
VTE type, 17.9% of those with PE, and 57.1% of those 
with DVT- only were treated as outpatients. Table 1 pro-
vides VTE patient characteristics stratified by VTE type 
and acute management strategy. Prevalence of out-
patient management increased over time for both VTE 
types from 2011 to 2018, from 16% to 23% for PE, and 
from 54% to 65% for DVT only (Figure). Furthermore, 
across both the PE and DVT- only groups, outpatient 
management was less prevalent among patients with 
cancer, those with higher Charlson comorbidity index 
scores, and those whose primary treatment was war-
farin as compared with a DOAC (Table 2). The propor-
tion managed acutely as an outpatient did not differ 
significantly by age or sex.
We also evaluated whether acute management 
strategy was associated with differential risk of inci-
dent bleeding and healthcare utilization that occurred 
in the primary treatment phase (ie, the first 6 months 
following the VTE event). Acute outpatient manage-
ment was associated with lower incident bleeding 
risk for both patients who initially presented with PE 
(hazard ratio, 0.71; 95% CI, 0.61, 0.82) and DVT- only 
(hazard ratio, 0.59; 95% CI, 0.54, 0.64) in the fully 
adjusted model (Table  3). Also, among patients with 
PE, the number of hospitalizations and days hospi-
talized was similar regardless of acute management 
strategy (Table  3). However, those who were acutely 
managed as an outpatient incurred fewer office visits 
(incidence rate ratio [95% CI], 0.88 [0.87, 0.89]) and 
emergency department visits (0.93 [0.90, 0.96]), in the 
fully adjusted model. Among DVT- only patients, acute 
outpatient management was associated with a lower 
number of hospitalizations, days hospitalized, office 
visits, and emergency department visits. For instance, 
in the fully adjusted model for the DVT- only group, the 
mean number of hospitalizations was 48% lower (inci-
dence rate ratio, 0.52; 95% CI, 0.50, 0.54) among pa-
tients initially managed as outpatients compared with 
those initially managed as inpatients.
For all analyses, sensitivity analyses were conducted 
requiring 6  months of enrollment in the MarketScan 
database before incident VTE. Findings were similar to 
those of the primary analyses.
DISCUSSION
In this US population of >200 000 insured patients with 
VTE, outpatient acute VTE management was common, 
Table 1. VTE Patient Characteristics by Acute Management and Whether the Event was PE* or DVT Only: MarketScan 2011 
to 2018†
Acute Management
Pulmonary Embolism* DVT (only)
Inpatient Outpatient Inpatient Outpatient
N (%) 17 936 (17.9%) 81 989 (82.1%) 57 372 (57.1%) 43 049 (42.9%)
Participant characteristics
Female, % 50.9 51.4 51.7 49.4
Age, y, mean±SD 57.4±15.4 58.8±16.2 58.6±16.5 57.0±15.6
Prevalent cancer, % 22.5 25.4 26.2 17.5
Charlson comorbidity index
Mean±SD 2.30±2.51 2.39±2.69 2.78±2.76 1.75±2.39
Score, %
0 (none noted) 29.9 33.4 25.4 45.1
1– 2 (mild) 35.1 30.1 31.4 28.8
3– 4 (moderate) 15.7 14.3 17.7 11.5
≥5 (severe) 19.3 22.2 25.5 14.6
Primary treatment OAC
DOAC 89.2 87.9 83.3 90.3
Warfarin 10.8 12.1 16.7 9.7
DOAC indicates direct oral anticoagulants; DVT, deep vein thrombosis; OAC, oral anticoagulant; PE, pulmonary embolism; and VTE, venous thromboembolism.
*PE, regardless of whether a DVT was present.
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being the selected strategy for 18% of PE cases and 
57% of DVT- only cases. For both VTE types, the use of 
acute outpatient management increased from 2011 to 
2018, the timeframe under study. As expected, outpa-
tient management was less common among patients 
with VTE with cancer or higher comorbidity scores. 
Overall, after acute treatment, healthcare utilization 
and incident hospitalized bleeding in the primary treat-
ment period were lower for patients with VTE whose 
acute management was as outpatients, as compared 
with those initially managed as inpatients. This is not 
surprising, because the clinical decision to treat as an 
outpatient would only be indicated in lower- risk indi-
viduals. These findings support current recommen-
dations and suggest that outpatient management is 
not associated with substantial harm in appropriate 
patients.
Prevalence of, and Trends in, Outpatient 
Acute VTE Management
During the period from 2011 to 2018 in the MarketScan 
data, 18% of PE cases and 57% of DVT- only cases 
were initially managed on an outpatient basis. Table 4 
summarizes findings from published observational 
studies reporting the prevalence of outpatient man-
agement in publications that included >1000 patients 
with VTE. As has been reviewed recently by Roy,3 
numerous smaller studies of outpatient PE manage-
ment have been published; however, these often were 
restricted to a small geographic setting and/or were 
conducted as part of an intervention (randomized or 
practice- based). Of the large PE studies, those from 
Canada reported high prevalences of acute outpatient 
management (Quebec 2000– 2009, 49%15; Ottawa 
2001– 2012,17 48%), though the Quebec study reported 
uncertainty about the validity of PE events.15 For US- 
based studies, the prevalence of outpatient PE acute 
management was much lower (6% for 2001– 2012;16 
5% for 2004– 201011). For DVT, the prevalence we re-
ported (57%) for the period 2011 to 2018 is similar to 
that reported by Fang (55%) for the timeframe from 
2004 to 201011 but higher than that reported between 
2007 and 2012 by Stein (34%).12 Both of these DVT 
studies were conducted in US populations.
In comparing prevalence of outpatient manage-
ment in the present analyses of MarketScan data-
bases for years 2011 to 2018 to those of prior studies, 
it is crucial to be mindful of the minimal overlap in time 
periods. Most of the prior studies took place before 
the widespread use of DOACs. It has been speculated 
that outpatient management would become even 
more prevalent with the adoption of DOACs,11 given 
their lower bleeding risk, reduced need for monitor-
ing, and all- oral treatment approaches. Like others, 
we also documented that outpatient management is 
more likely in healthier individuals. For instance, in the 
Nationwide Emergency Department Sample, 63% of 
those relatively young (18– 50 years) and with no co-
morbidities were treated at home.12
The rising use of acute outpatient management is 
consistent with that observed in other studies. For DVT, 
Figure. Trends in outpatient acute venous thromboembolism management by whether the event 
was pulmonary embolism (PE)* or DVT only: MarketScan 2011 to 2018**.
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the prevalence increased from 31.6% in 2007 to 37.4% 
in 2012, in an analysis of the Nationwide Emergency 
Sample.12 Outpatient management of PE was also 
shown to increase from 2000 to 2009 in data from 
Quebec.15 As clinical experience with DOAC grows, it 
will be informative to evaluate how acute VTE manage-
ment changes over time.11
Acute Outpatient VTE Management and 
Subsequent Healthcare Utilization and 
Major Bleeding Events
Current guidelines2 recommended outpatient PE 
management in some settings based on (1) 2 trials 
that randomized patients with acute PE to shorter27 
or no treatment in the hospital28 compared with 
being treated in the hospital for a longer period, (2) 
observational studies of outpatient acute PE man-
agement,3 and (3) extrapolating from clinical experi-
ence and trials of outpatient acute DVT treatment. 
Furthermore, a 2017 comprehensive review of out-
patient management in the context of PE, which 
summarized both trials and observational studies, 
concluded that “outpatient management appears 
to be feasible and safe for many patients with PE.”3 
However, the existing evidence is incomplete; the 
current guidelines2 have a Grade 2B recommenda-
tion and state: “The quality of evidence for treatment 
of acute PE at home remains moderate because of 
marked imprecision.”
In the present evaluation of healthcare utilization 
and incident major bleeding postacute management 
(ie, in the VTE primary treatment period), we observed 
that in the contexts of both PE and DVT- only, patients 
whose initial management was outpatient had fewer 
bleeding events. Healthcare utilization was also lower 
in the DVT- only group managed acutely as outpatients, 
compared with the group managed acutely as inpa-
tients. For patients with PE, hospitalization rates did 
not differ by acute management strategy, but office 
and emergency department visits were lower among 
patients with VTE managed initially as outpatients. 
We acknowledge that these results are confounded 
by indication; patients managed acutely as outpa-
tients were undoubtedly healthier, as evidenced by 
the lower Charlson comorbidity index burden in this 
group. However, the findings are useful for describing 
the general clinical experience of patients with VTE 
managed acutely in outpatient and inpatient settings, 
respectively.
Strengths and Limitations
The primary strengths of this analysis are the large 
number of VTE cases in a real- world, contempo-
rary setting. The key limitations include the likeli-
hood of confounding because of indication and lack 
of detailed information to verify VTE case status, 
severity of VTE, and burden of comorbidities and 
other factors that may have influenced a clinician’s 
decision to manage a VTE case as inpatient or out-
patient. However, throughout we used validated 
algorithms to define medical conditions.21,22,24 Our 
VTE definition allowed both inpatient and outpatient 
management, and required use of OACs around the 
time of the VTE event. In a validation study of this 
definition in an independent population, the positive 
predictive value was high, at 91%.21 We acknowl-
edge that indication bias is almost certainly present 
in the determination of who is acutely managed on 
an outpatient basis, and in our data it is impossi-
ble to fully control for factors that influenced acute 
management decisions. The findings provide novel 
information about secular trends in acute manage-
ment of VTE, though generalizability to individuals 
with no insurance and those working for small com-
panies may be limited. However, these data do not 
reveal who should be managed as an outpatient 
Table 2. Adjusted Prevalence of VTE Patient 
Characteristics by Acute Management and Whether the 
Event was PE* or DVT Only: MarketScan 2011 to 2018†
Initial Management




Male 18.2 (18.0, 18.5) 57.9 (57.5, 58.3)
Female 17.5 (17.2, 17.8) 56.7 (56.3, 57.1)
Age category
<45 y 18.5 (18.1, 18.9) 58.3 (57.7, 58.8)
45– 54 y 19.0 (18.6, 19.4) 59.1 (58.6, 59.7)
55– 64 y 16.5 (16.2, 16.8) 55.0 (54.5, 55.5)
65– 74 y 18.4 (18.0, 18.8) 58.2 (57.5, 58.8)
≥75 y 17.7 (17.3, 18.1) 57.0 (56.4, 57.6)
Cancer
Yes 15.0 (14.7, 15.4) 52.2 (51.6, 52.8)
No 18.7 (18.4, 19.0) 58.6 (58.3, 59.0)
Charlson comorbidity index score
0 (none noted) 25.4 (25.0, 25.8) 67.6 (67.2, 68.0)
1– 2 (mild) 16.4 (16.1. 16.7) 54.6 (54.1, 55.1)
3– 4 (moderate) 13.2 (12.9, 13.6) 48.4 (47.7, 49.1)
≥5 (severe) 13.1 (12.8, 13.4) 48.0 (47.4, 48.6)
Primary treatment OAC
DOAC 18.4 (18.2, 18.7) 58.5 (58.1, 58.8)
Warfarin 13.4 (13.0, 13.8) 49.1 (48.4, 49.9)
DOAC indicates direct oral anticoagulants; DVT, deep vein thrombosis; 
OAC, oral anticoagulant; PE, pulmonary embolism; and VTE, venous 
thromboembolism.
*Pulmonary embolism, regardless of whether or not a DVT was present.
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versus inpatient for the acute treatment of VTE. An 
additional limitation of the present analysis is that 
we did not evaluate mortality as an outcome since 
MarketScan lacks information on out- of- hospital 
death.
CONCLUSIONS
In this analysis of 200  346 patients with VTE, we 
demonstrated increases in the prevalence of outpa-
tient acute management from 2011 to 2018, for both 
PE and DVT- only cases. In 2018, we estimate that 
23% of PE cases and 65% of DVT- only cases were 
managed on an outpatient basis. Cases managed as 
outpatients were more likely to not have cancer, have 
fewer comorbidities, and be prescribed a DOAC for 
their primary treatment. Furthermore, we show that 
healthcare utilization and major bleeding incidence 
was lower among VTE cases initially managed on an 
outpatient basis. These data provide a contemporary 
context regarding the patterns of acute outpatient 
VTE management, as well as outcomes, in a large, 
insured US population.
Further clinical studies are warranted to determine 
which clinical populations could most benefit from out-
patient versus inpatient treatment of VTE.
Table 3. Incident Hospitalized Bleeding and Healthcare Utilization According to VTE Presentation and Acute VTE 
Management: MarketScan 2011 to 2018
PE* DVT Only
Inpatient Outpatient Inpatient Outpatient
N (%) 81 989 (82.1%) 17 936 (17.9%) 43 049 (42.9%) 57 372 (57.1%)
Hospitalized bleeding
N hospitalized bleed 1295 210 920 506
N total 81 989 17 936 43 049 57 372
HR (95% CI)
Model 1† 1 (Ref) 0.71 (0.61, 0.82) 1 (Ref) 0.53 (0.49, 0.58)
Model 2‡ 1 (Ref) 0.71 (0.61, 0.82) 1 (Ref) 0.59 (0.54, 0.64)
Healthcare utilization
Hospitalizations, N
Crude mean±SD 0.23±0.65 0.21±0.60 0.30±0.77 0.13±0.45
IRR (95% CI)
Model 1† 1 (Ref) 0.92 (0.88, 0.97) 1 (Ref) 0.43 (0.41, 0.44)
Model 2‡ 1 (Ref) 0.95 (0.90, 1.00) 1 (Ref) 0.52 (0.50, 0.54)
Days hospitalized, N
Crude mean±SD 1.69±6.17 0.21±0.60 0.30±0.77 0.13±0.45
IRR (95% CI)
Model 1† 1 (Ref) 0.90 (0.83, 0.97) 1 (Ref) 0.35 (0.33, 0.38)
Model 2‡ 1 (Ref) 0.96 (0.89, 1.04) 1 (Ref) 0.43 (0.40, 0.46)
Office visits, N
Crude mean±SD 8.33±6.52 7.33±6.29 8.06±6.62 6.51±5.89
IRR (95% CI)
Model 1† 1 (Ref) 0.88 (0.87, 0.89) 1 (Ref) 0.80 (0.79, 0.81)
Model 2‡ 1 (Ref) 0.88 (0.87, 0.89) 1 (Ref) 0.86 (0.85, 0.87)
Emergency Department visits, N
Crude mean±SD 0.53±1.30 0.48±1.17 0.47±1.24 0.30±0.97
IRR (95% CI)
Model 1† 1 (Ref) 0.92 (0.89, 0.96) 1 (Ref) 0.64 (0.62, 0.66)
Model 2‡ 1 (Ref) 0.93 (0.90, 0.96) 1 (Ref) 0.73 (0.71, 0.75)
DOAC indicates direct oral anticoagulant; DVT, deep vein thrombosis; HR, hazard ratio; IRR, incidence rate ratio; OAC, oral anticoagulant; PE, pulmonary 
embolism; and VTE, venous thromboembolism.
*Pulmonary embolism, regardless of whether or not a DVT was present.
†Model 1: Adjusted for age, sex, and initial OAC (OAC, DOAC, or warfarin).
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Table S1. ICD-9-CM and ICD-10-CM codes used to define incident VTE. 
 
Revision VTE codes 
ICD-9-CM 415.1x, 451.1x, 453.2, 453.4x, 453.82, 453.83, 453.84, 453.85, 453.86, 
453.87, 453.89, 453.9 
ICD-10-CM I26.0x, I26.9x, I80.1x, I80.20x, I82.210, I80.22x, I80.23x, I80.29x, 
I82.40x, I82.41x, I82.42x, I82.43x, I82.44x, I82.49x, I82.4Yx, I82.4Zx, 
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